Literature DB >> 9005896

Hypercoagulability and hypofibrinolysis in primary osteoarthritis.

P A Cheras1, A N Whitaker, E A Blackwell, T J Sinton, M D Chapman, K A Peacock.   

Abstract

Histologic evidence of venous thrombosis and lipid abnormalities have previously been reported in osteoarthritis. Hypofibrinolysis has been recorded in patients with ischemic necrosis of bone, and it has been proposed as a major cause of osteonecrosis. This study determines whether systemic evidence of coagulation and lipid abnormalities could be detected in osteoarthritis. Global and specific tests were used to assess coagulability and fibrinolysis in 44 patients with degenerative osteoarthritis of the hip and 52 matched control subjects. In patients with osteoarthritis, an increase in factor VIIlc, increased platelet sensitivity over a range of adenosine diphosphate concentrations (0.05 micromol/L-4 micromol/L) and elevated D dimer levels were found. Euglobulin clot lysis time was prolonged in this group and plasminogen activator inhibitor Type 1 activity was increased. Relative hyperlipidemia was observed in the osteoarthritis group, with increased cholesterol, low density lipoprotein cholesterol, and triglyceride levels. It is concluded that there is a hypercoagulable and prothrombotic condition in osteoarthritis, with hypofibrinolysis and indirect evidence of increased fibrin generation. The possible contribution of lipid abnormalities to hemostatic imbalance in osteoarthritis is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005896

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  11 in total

1.  Ligneous conjunctivitis: biochemical evidence for hypofibrinolysis.

Authors:  M L Ramsby; P C Donshik; G S Makowski
Journal:  Inflammation       Date:  2000-02       Impact factor: 4.092

2.  Biochemical and morphological alterations in lungs induced by experimental inhibition of fibrinolytic activity.

Authors:  Izzet Hoşgör; Aysen Yarat; Nukhet Tüzüner; Faruk Alkan; Nesrin Emekli; Sarfraz Ahmad
Journal:  Mol Cell Biochem       Date:  2002-12       Impact factor: 3.396

3.  Interaction of amorphous calcium phosphate with fibrin in vitro causes decreased fibrinolysis and altered protease profiles: implications for atherosclerotic disease.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

4.  Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?

Authors:  Wesley E Stites; Jeffrey W Froude
Journal:  Med Hypotheses       Date:  2006-10-24       Impact factor: 1.538

5.  Pathophysiology and risk factors for osteonecrosis.

Authors:  Kalpit N Shah; Jennifer Racine; Lynne C Jones; Roy K Aaron
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

6.  Factors associated with change in pain and disability over time: a community-based prospective observational study of hip and knee osteoarthritis.

Authors:  Tim J Peters; Caroline Sanders; Paul Dieppe; Jenny Donovan
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

7.  Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.

Authors:  N Busso; J Dudler; R Salvi; V Péclat; V Lenain; S Marcovina; R Darioli; P Nicod; A K So; V Mooser
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

8.  Fibrin concentration affects ACL fibroblast proliferation and collagen synthesis.

Authors:  Patrick Vavken; Shilpa M Joshi; Martha M Murray
Journal:  Knee       Date:  2010-01-18       Impact factor: 2.199

9.  Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality.

Authors:  M M Haara; P Manninen; H Kröger; J P A Arokoski; A Kärkkäinen; P Knekt; A Aromaa; M Heliövaara
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

10.  The association of eNOS gene polymorphism with avascular necrosis of femoral head.

Authors:  Liwen Zheng; Wanchun Wang; Jiangdon Ni; Zhihong Li; Tao Xiao
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.